title: Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice.
abstract: Oil of mustard (OM) is a potent neuronal activator that promotes allodynia and hyperalgesia within minutes of application. In this study, OM was used to induce an acute colitis. We also investigated whether intracolonic OM-induced inflammation alters gastrointestinal (GI) function over a longer time frame as a model of postinflammatory irritable bowel syndrome (PI-IBS). Mice given a single administration of 0.5% OM developed a severe colitis that peaked at day 3, was reduced at day 7, and was absent by day 14. At the peak response, there was body weight loss, colon shrinkage, thickening and weight increases, distension of the proximal colon, and diarrhea. Macroscopic inspection of the distal colon revealed a discontinuous pattern of inflammatory damage and occasional transmural ulceration. Histological examination showed loss of epithelium, an inflammatory infiltrate, destruction of mucosal architecture, edema, and loss of circular smooth muscle architecture. OM administration increased transit of a carmine dye bolus from 58% of the total length of the upper GI tract in untreated age-matched controls to as high as 74% when tested at day 28 post-OM. Mice in the latter group demonstrated a significantly more sensitive response to inhibition of upper GI transit by the mu-opioid receptor agonist loperamide compared with normal mice. OM induces a rapid, acute, and transient colitis and, in the longer term, functional changes in motility that are observed when there is no gross inflammation and thereby is a model of functional bowel disorders that mimic aspects of PI-IBS in humans.
authors.affiliation: Enterology Research Team, Johnson and Johnson Pharmaceutical, Research and Development, Welsh and McKean Roads, PO Box 776, Spring House, PA, 19477-0776, USA. ekimball@prdus.jnj.com
authors.forename: Edward S
authors.initials: ES
authors.lastname: Kimball
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Palmer
authors.forename: Michael R
authors.initials: MR
authors.lastname: D'Andrea
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Hornby
authors.forename: Paul R
authors.initials: PR
authors.lastname: Wade
mesh_terms: D000208:Acute Disease; D000818:Animals; D000930:Antidiarrheals / Q000494:pharmacology; D003092:Colitis / Q000503:physiopathology* / Q000662:veterinary; D003106:Colon / Q000276:immunology / Q000473:pathology; D003967:Diarrhea / Q000209:etiology; D004195:Disease Models, Animal; D005769:Gastrointestinal Motility / Q000502:physiology*; D007249:Inflammation; D007420:Intestine, Large / Q000502:physiology; D007421:Intestine, Small / Q000502:physiology; D043183:Irritable Bowel Syndrome / Q000503:physiopathology* / Q000662:veterinary; D008139:Loperamide / Q000494:pharmacology; D008297:Male; D051379:Mice; D009149:Mustard Plant; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects*; D010938:Plant Oils; D014456:Ulcer / Q000473:pathology
chemical_list: D000930:Antidiarrheals; D010936:Plant Extracts; D010938:Plant Oils; D008139:Loperamide; C027793:mustard oil